SAN ANTONIO – A local doctor involved in a study for the first drug approved by the FDA to treat COVID-19 says he is encouraged by the development.
The anti-viral drug has been fast-tracked by U.S. regulators for emergency use. Studies suggest that remdesivir appears to help some severe COVID-19 patients recover faster, a milestone in the global search for effective therapies against the coronavirus.
Dr. Thomas Patterson, professor in the Long School of Medicine and chief of the Division of Infectious Diseases at UT Health San Antonio, is leading a study site on the drug in San Antonio that also includes more than 75 other sites in the U.S.
“It’s very exciting to be involved in a clinical trial that is moving forward so quickly toward helping patients,” Dr. Patterson said. “This is the first anti-viral drug that has been shown to benefit patients with COVID-19 in a randomized clinical trial.”
In a statement, the UT Health Science Center in San Antonio said the authorization means that “hospitalized COVID-19 patients meeting criteria for use can receive remdesivir, which is now the standard of care.”
With the approval, the use of the drug will be expanded to hospitals that were not initially part of the trial, said Dr. Jason Bowling, an infectious disease physician at UT Health System.
It can be given to adults and children who have a severe case of COVID-19, he said.
Now, doctors here and across the country will begin a second phase of researching the drug while in action, Patterson said. Starting next week, hospitalized patients will be treated with remdesivir, “and will be randomized to receive additional agents, which are hoped to further improve outcomes.”
Watch more from a local doctor involved in the study above, and read more context about the new anti-viral drug from the Associated Press below.
The Food and Drug Administration cleared Gilead Science’s intravenous drug for hospitalized patients with “severe disease,” such as those experiencing breathing problems requiring supplemental oxygen or ventilators.
President Donald Trump announced the news at the White House alongside Gilead CEO Daniel O’Day and Food and Drug Administration Commissioner Stephen Hahn.
“This was lightning speed in terms of getting something approved” said Hahn, calling the drug “an important clinical advance.”
The FDA acted after preliminary results from a government-sponsored study showed that the drug, remdesivir, shortened the time to recovery by 31%, or about four days on average, for hospitalized COVID-19 patients.
Those given the drug were able to leave the hospital in 11 days on average vs. 15 days for the comparison group. The drug may also help avert deaths, but that effect is not yet large enough for scientists to know for sure.
Dr. Sameer Khanijo, a critical care specialist, said he wants to see additional studies to clarify the drug's benefit.
“I don’t think this is a cure yet, but I think it’s starting to point us in the right direction,” said Khanijo of North Shore University Hospital in New York. “As a society it’s nice to have something that will help stem the tide of this disease.”
The FDA said preliminary results from the government study warranted Friday's decision, though regulators acknowledged “there is limited information known about the safety and effectiveness of using remdesivir.”
The drug's side effects include potential inflammation of the liver and problems related to its infusion, which could lead to nausea, vomiting, sweating and low blood pressure. Information about dosing and potential safety issues will be provided to physicians and patients, the FDA said.
The National Institutes of Health’s Dr. Anthony Fauci said Wednesday the drug would become a new standard of care for severely ill COVID-19 patients. Remdesivir, which blocks an enzyme the virus uses to copy its genetic material, has not been tested on people with milder illness.
The FDA authorized the drug under its emergency powers to quickly speed the availability of experimental drugs, tests and other medical products during public health crises.
In normal times the FDA requires “substantial evidence” of a drug’s safety and effectiveness, usually through one or more large, rigorously controlled patient studies. But during public health emergencies the agency can waive those standards and require only that an experimental treatment's potential benefits outweigh its risks.
Gilead has said it will donate its currently available stock of the drug and is ramping up production to make more. It said the U.S. government would coordinate distribution of remdesivir to parts of the country that need it most.
No drugs are currently FDA-approved for treating the coronavirus, and remdesivir will still need formal approval.
The FDA can convert the drug’s status to full approval if Gilead or other researchers provide additional data of remdesivir’s safety and effectiveness.
“This is a very, very early stage so you wouldn’t expect to have any sort of full approval at this point,” said Cathy Burgess, an attorney specializing in FDA issues. “But obviously they want to get this out to patients as quickly as possible.”
The FDA previously allowed narrow use of a malaria drug, hydroxychloroquine, for hospitalized patients who were unable to take part in ongoing studies of the medication. Trump repeatedly promoted it as a possible COVID-19 treatment, but no large high-quality studies have shown the drug works for that and it has significant safety concerns.
The FDA warned doctors late last month against prescribing the drug outside of hospital or research settings, due to risks of sometimes fatal heart side effects. The agency made the announcements after receiving new reports of injury and death with the medication, which is also used to treat lupus and rheumatoid arthritis.
Two small studies published Friday add to concerns about hydroxychloroquine. Critically ill COVID-19 patients given the pill-based drug were prone to heart rhythm problems, and for many risks mounted when it was combined with an antibiotic, the studies found.
Marchione reported from Milwaukee. AP Medical Writer Lindsey Tanner contributed to this report from Chicago.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.